01 Industry overview
The mrna cancer vaccine industry at a glance
The mRNA cancer vaccine industry remains largely investigational, but its 2025 market was estimated at $1.28 billion and its leading personalized vaccine program reported positive Phase 3 melanoma results in 2026.
- $1.28B[9]
- Market size, 2025
- 30.2%[9]
- Forecast CAGR, 2026–2035
- 1,089[10]
- Phase 3 melanoma enrollment
- $250M[11]
- Merck option payment, 2022
- Market size
- The global mRNA cancer vaccines and therapeutics market was valued at $1.28 billion in 2025, according to Emergen Research. This estimate covers mRNA cancer vaccines together with related therapeutics, so it should not be interpreted as vaccine-only product sales.[9]
- Forecast & CAGR
- The combined mRNA cancer vaccines and therapeutics market is projected to reach $18.62 billion by 2035, representing a 30.2% CAGR from 2026 to 2035. Separately, Custom Market Insights forecasts a 6.9% CAGR for its narrower mRNA cancer vaccine market definition from 2025 to 2034, illustrating the effect of scope differences.[9][12]
- Market share & regions
- Reliable public sources provide limited region-specific share data for the mRNA cancer vaccine segment. Emergen Research reports that the United States held the largest revenue share within North America in 2025, while broader cancer-vaccine data from Grand View Research placed North America at 35.5% of global revenue in 2025; the latter is not mRNA-specific.[9][13]
- Segmentation
- Market reports segment mRNA cancer vaccines by cancer type, including melanoma, non-small-cell lung cancer, prostate, pancreatic and colorectal cancers; by use case, including therapeutic and preventive vaccines; and by delivery mechanism, including lipid nanoparticles, polymer-based carriers and electroporation. Clinical development is concentrated in therapeutic, personalized neoantigen vaccines and shared-antigen vaccines.[12][14]
- Key players & concentration
- The leading commercial-development groups are Moderna with Merck, BioNTech with Genentech, and CureVac, alongside academic and smaller biotechnology programs. Moderna and Merck’s Phase 3 INTerpath-001 melanoma study has estimated enrollment of 1,089 participants and 165 trial locations, indicating that late-stage development is concentrated among a small number of large pharmaceutical partnerships.[10][15][16]
- Trends, drivers & challenges
- The main growth driver is the ability to encode patient-specific neoantigens and combine vaccination with immune-checkpoint inhibitors. The principal challenges are individualized manufacturing, tumor sequencing, logistics and the time required to produce a patient-specific product; Nature research describes personalized manufacturing as complex and time-intensive.[14][8]
- M&A
- The sector is being shaped more by licensing and strategic collaborations than by acquisitions. Merck and Moderna began their personalized cancer-vaccine collaboration in 2016 with a reported $200 million upfront payment; in 2022, Merck exercised its option for joint development and commercialization and paid Moderna $250 million, with costs and profits to be shared equally.[17][11]
- Regulation
- In the United States, therapeutic mRNA cancer vaccines are regulated as investigational biological products and generally require an Investigational New Drug application before clinical testing. FDA guidance for therapeutic cancer vaccines addresses clinical considerations for products intended to treat patients with an existing cancer diagnosis; the agency’s guidance was issued in 2011 and remains the principal cancer-vaccine-specific document identified in the sources reviewed.[18]
- Latest news
- In 2026, Moderna and Merck reported that the Phase 3 INTerpath-001 study of intismeran autogene, formerly V940 or mRNA-4157, plus pembrolizumab met its primary recurrence-free-survival endpoint and a secondary distant-metastasis-free-survival endpoint in patients with completely resected stage IIB–IV melanoma. The therapy remains investigational and requires regulatory review before any commercial launch.[8][10]
02 Ranking
Top 8 Companies in the Mrna Cancer Vaccine Industry
The leading companies in the mrna cancer vaccine industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Roche stands out for individualized mRNA cancer immunotherapy because its BNT122 candidate is developed with BioNTech, while Genentech focuses on mRNA cancer vaccine candidates since it collaborated with BioNTech on BNT122 in Phase 2.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in personalized mRNA oncology vaccines
Roche
CH
Ranked #1 · 9.4 · Personalized mRNA oncology vaccines
Why we picked it: Roche ties its personalized mRNA cancer immunotherapy work to BNT122 alongside BioNTech and reports an R&D spend equal to 19.8% of revenue.
#2 overall
Genentech
US
Ranked #2 · 9.3 · Personalized mRNA oncology vaccines
Why we picked it: Genentech’s tie to BNT122 in Phase 2 positions it around individualized neoantigen vaccine development.
Leader in mRNA vaccine adjuvant platforms
Argenx
NL
Ranked #3 · 9.1 · mRNA vaccine adjuvant platforms
Why we picked it: Argenx centers its mRNA cancer-vaccine combinations on cusatuzumab and reports an operating margin of 24.8%.
Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Roche Personalized mRNA oncology vaccines · CH | 9.4 | 9.9 | 8.4 | 9.2 | 9.9 | |
Company snapshot · Roche · Data as of November 20, 2026 Roche and BioNTech are developing individualized mRNA cancer immunotherapy candidate BNT122.[1]
| |||||||
| 2 | Genentech Personalized mRNA oncology vaccines · US | 9.3 | 8.4 | 9.6 | 9.8 | 9.9 | |
Company snapshot · Genentech · Data as of November 20, 2026 Collaborated with BioNTech on individualized mRNA cancer vaccine BNT122 in Phase 2.[19]
| |||||||
| 3 | Argenx mRNA vaccine adjuvant platforms · NL | 9.1 | 7.9 | 9.7 | 9.9 | 9.3 | |
Company snapshot · Argenx · Data as of November 20, 2026 Cusatuzumab explored in combination with mRNA cancer vaccine approaches.[20]
| |||||||
| 4 | Merck Personalized mRNA oncology vaccines · US | 9.0 | 9.8 | 8.7 | 7.7 | 9.3 | |
Company snapshot · Merck · Data as of November 20, 2026 Merck co-develops Moderna's personalized mRNA cancer vaccine with KEYTRUDA.[21]
| |||||||
| 5 | Moderna Personalized mRNA oncology vaccines · US | 8.7 | 9.0 | 7.9 | 8.4 | 9.9 | |
Company snapshot · Moderna · Data as of November 20, 2026 Moderna is advancing intismeran, an individualized mRNA cancer therapy, with eight Phase 2 and 3 trials.[22]
| |||||||
| 6 | BioNTech mRNA cancer vaccines and oncology immunotherapies · DE | 8.7 | 9.1 | 7.7 | 8.2 | 9.9 | |
Company snapshot · BioNTech · Data as of November 20, 2026 BioNTech's pipeline includes individualized and off-the-shelf mRNA cancer vaccines.[15]
| |||||||
| 7 | CureVac mRNA cancer vaccine candidates, global · DE | 8.5 | 7.9 | 9.9 | 7.5 | 8.7 | |
Company snapshot · CureVac · Data as of November 20, 2026 Phase 1 trial of CV8101 mRNA cancer immunotherapy in solid tumors reported in 2020.[23]
| |||||||
| 8 | eTheRNA immunotherapies mRNA-based cancer immunotherapy, Belgium · BE | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | |
Company snapshot · eTheRNA immunotherapies · Data as of November 20, 2026 TriMix mRNA cancer immunotherapy in Phase 2 trials for melanoma.[24]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 20). Top 8 companies in the mrna cancer vaccine industry. In Mrna Cancer Vaccine Industry Statistics. Gitnux. https://gitnux.org/mrna-cancer-vaccine-industry-statistics/#top-companies
Global industry-sponsored mRNA therapeutic vaccine clinical trials in oncology by indication, initiated since 2022
Solid tumors leads with 13.
03 Trends & forecasts
Top 10 Mrna Cancer Vaccine Industry Trends & Forecasts 2027
What is changing in the mrna cancer vaccine industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Phase 3 validation accelerates demand
High confidenceIn August 2026, Moderna and Merck reported that the Phase 3 INTerpath-001 study met its recurrence-free-survival and distant-metastasis-free-survival endpoints in 1,137 patients with resected stage IIB–IV melanoma. This was the first positive Phase 3 readout for an individualized mRNA cancer therapy.[17]
Forecast 2027: In 2027, demand for personalized mRNA cancer-vaccine development, clinical manufacturing and companion diagnostics should increase sharply as sponsors seek to replicate the melanoma result in other tumor types. Commercial sales will remain limited until regulatory filings and approvals progress.
02Melanoma remains the lead indication
High confidenceINTerpath-001 enrolled 1,137 patients with high-risk melanoma, while the earlier KEYNOTE-942 Phase 2 study enrolled 157 patients in the same postoperative setting. Current late-stage development therefore remains concentrated in adjuvant melanoma rather than broad preventive vaccination.[17][11]
Forecast 2027: In 2027, melanoma is likely to remain the commercial and regulatory reference indication, while lung, renal, bladder and other cancers provide the principal expansion opportunities. Evidence in those indications will determine whether the market broadens beyond melanoma.
03Checkpoint combinations remain standard
High confidenceThe leading Phase 3 program tests intismeran autogene together with pembrolizumab against pembrolizumab alone. Merck and Moderna’s collaboration was explicitly built around combining personalized mRNA vaccines with KEYTRUDA and other immuno-oncology agents.[17][11]
Forecast 2027: In 2027, most pivotal mRNA cancer-vaccine trials will continue to use checkpoint inhibitors as the backbone comparator or combination partner. Standalone vaccine trials are likely to remain a minority, particularly in advanced disease.
04Personalized neoantigens dominate development
High confidenceIntismeran is designed from the unique mutation profile of each patient’s tumor, and the EMA identifies V940/mRNA-4157 as modified mRNA encoding individual patient-specific tumor neoantigens. This approach is distinct from fixed vaccines that target shared tumor antigens.[17][25]
Forecast 2027: In 2027, personalized neoantigen products should continue to attract the largest share of strategic investment and clinical attention. Shared-antigen and off-the-shelf programs will remain important where turnaround time or manufacturing cost makes individualized products impractical.
05Pipeline expansion moves beyond melanoma
High confidenceClinicalTrials.gov lists ongoing intismeran studies in additional settings, including non-small-cell lung cancer, while the EMA product record identifies planned indications including renal-cell, urothelial and cutaneous squamous-cell carcinomas. BioNTech also lists individualized mRNA cancer immunotherapy and fixed-antigen RNA vaccine programs in its pipeline.[10][25][15]
Forecast 2027: In 2027, trial activity should broaden toward lung, bladder, renal, colorectal, pancreatic and breast cancers. The most credible expansion will remain in adjuvant or minimal-residual-disease settings, where immune priming has more time to work.
06Individualized manufacturing scales gradually
High confidenceThe original Merck–Moderna collaboration described a rapid-cycle, small-batch process intended to supply patient-specific vaccines within weeks and funded construction of a GMP manufacturing facility. The need to sequence each tumor and manufacture a separate batch remains a central operational constraint.[11]
Forecast 2027: In 2027, manufacturers will invest in automation, standardized analytical testing and regional production capacity rather than conventional large-batch vaccine plants. Capacity will expand, but turnaround time and batch release will still limit use in rapidly progressing cancers.
07Tumor sequencing becomes essential infrastructure
High confidencePersonalized products are designed from each patient’s tumor mutation signature, and clinical trials require patients to undergo tumor-based selection and manufacturing before treatment. The EMA describes V940 as encoding patient-specific tumor neoantigens rather than a universal antigen set.[25][10]
Forecast 2027: In 2027, demand should rise for tumor sequencing, bioinformatics, HLA typing and neoantigen-prediction services linked to treatment centers. Diagnostic turnaround will increasingly be judged alongside vaccine manufacturing time as a determinant of patient access.
08Lipid nanoparticles retain delivery leadership
Medium confidenceA 2026 Phase 1 self-amplifying RNA cancer-vaccine study describes delivery in lipid nanoparticles, while the EMA’s mRNA quality guideline separately identifies delivery systems and self-amplifying mRNA as active regulatory-development topics. These sources indicate that LNPs remain the principal clinical delivery platform even as alternatives are explored.[10][25]
Forecast 2027: In 2027, LNP-based formulations should remain the dominant delivery approach for clinical cancer-vaccine programs. Polymer systems, lipoplexes and self-amplifying RNA will progress mainly as attempts to improve dose efficiency, tolerability or tissue targeting.
09Self-amplifying RNA enters early trials
High confidenceImmunomic Therapeutics’ ITI-5000 is being studied in a Phase 1 trial for stage II–III triple-negative breast cancer, with an estimated enrollment of 60 participants and a last update posted in September 2026. The product uses self-amplifying RNA delivered in lipid nanoparticles.[10]
Forecast 2027: In 2027, self-amplifying RNA should generate additional early clinical data but remain commercially immature. Its near-term impact will be technological benchmarking against conventional mRNA rather than material market-share displacement.
10Regulatory pathways remain investigational
High confidenceThe FDA’s therapeutic-cancer-vaccine guidance states that sponsors should submit an Investigational New Drug application before clinical testing and use clinical studies to support a later biologics license application. The guidance remains the principal U.S. cancer-vaccine-specific framework identified in the reviewed sources.[18]
Forecast 2027: In 2027, regulatory engagement will intensify around individualized-product comparability, release testing, sequencing algorithms and manufacturing changes. Approval decisions will likely establish precedents for platform-based submissions and patient-specific batch validation.
04 Statistics
Technology
Clinical development skews early: 45% of 99 registered trials were Phase I as of December 2024. Individualized-neoantigen programs show active recruiting counts in mid-2024 listings.
R&D, patents and design rights in the mrna cancer vaccine industry
- 45% of 99 registered mRNA cancer-vaccine trials were Phase I, 32% Phase I/II, and 23% Phase II/III as of December 2024.[1]
- 23 actively recruiting individualized-neoantigen cancer-vaccine trials were listed on ClinicalTrials.gov on August 5, 2024, including 6 trials started in 2024.[2]
- 99 registered mRNA cancer-vaccine clinical trials covered 15 cancer types as of December 2024, based on a comprehensive clinical-trial-registry analysis.[1]
- 27 mRNA cancer-vaccine trials were identified from 551 initially screened studies using ClinicalTrials.gov natural-language processing; 10 were Phase I, 5 Phase I/II, and 6 Phase II.[3]
05 Statistics
Market Intelligence
Market estimates vary by category scope: $1.28B in 2025 is paired with a broader “vaccines and therapeutics” framing. Pipeline reviews identify 27 cancer-trial efforts using ClinicalTrials.gov inputs in 2025.
Market size, volume and shipments in the mrna cancer vaccine industry
- $71.22 billion was the 2025 global market size for the publisher-defined “mRNA cancer vaccines and therapeutics” category, including individualized cancer-treatment mRNA vaccines and broader infectious-disease vaccine applications.[4]
- $155 million was the estimated 2024 global market value for mRNA cancer vaccines and therapeutics, using the publisher’s category definition.[5]
Company counts and size structure in the mrna cancer vaccine industry
- 27 mRNA cancer-vaccine clinical trials were identified in a 2025 global pipeline analysis based on 551 mRNA clinical trials.[3]
- 102 cancer-related mRNA vaccine and therapeutic candidates were identified in the global noncommunicable-disease clinical pipeline reviewed through the study’s 2026 analysis.[6]
- 36 distinct developers or development collaborations used lipid-nanoparticle formulations across the reviewed mRNA vaccine and therapeutic pipeline, including cancer programs.[6]
- 85 developers or development collaborations were identified across the reviewed global mRNA vaccine and therapeutic pipeline, which included cancer applications.[6]
06 Statistics
Strategy & Growth
Manufacturing capacity moves from lab to clinical throughput, including clinical-batch supply starting in September 2025 for intismeran autogene. Capacity expansion plans include up to 500,000 doses per year after two BioNTainer units in 2026.
Capacity expansion in the mrna cancer vaccine industry
- A new Mainz, Germany facility completed in 2025 is designed to serve a high four-digit number of patients annually for personalized mRNA oncology products, with a manufacturing-license target of 2027.[7]
- Moderna’s Marlborough, Massachusetts facility began supplying clinical batches of the personalized mRNA cancer vaccine intismeran autogene in September 2025, marking a production scale-up for the oncology program.[8]
- Up to 500,000 doses per year of clinical-trial material or vaccines are planned after two BioNTainer units are installed in 2026 at BioNTech’s Kigali facility; this is broader mRNA-vaccine capacity, not cancer-vaccine-only capacity.[7]
Key questions about the mrna cancer vaccine industry
What is the 2025 market size for mRNA cancer vaccines?
How fast is the market expected to grow in the coming decade?
Which companies lead the mrna cancer vaccine industry?
What technology shifts are shaping development programs in 2026?
How is the industry structured around partnerships and late-stage execution?
Where is clinical validation most advanced, and what enrollment does it involve?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 20). Mrna Cancer Vaccine Industry Statistics. Gitnux. https://gitnux.org/mrna-cancer-vaccine-industry-statistics
Samuel Norberg. "Mrna Cancer Vaccine Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/mrna-cancer-vaccine-industry-statistics.
Samuel Norberg. 2026. "Mrna Cancer Vaccine Industry Statistics." Gitnux. https://gitnux.org/mrna-cancer-vaccine-industry-statistics.
Sources & references
25 sources cited across this report
pmc.ncbi.nlm.nih.gov
jitc.bmj.com
pubs.rsc.org
thebusinessresearchcompany.com
- intelmarketresearch.com
doi.org
investors.biontech.de
modernatx.com
emergenresearch.com
clinicaltrials.gov
merck.com
custommarketinsights.com
grandviewresearch.com
nature.com
biontech.com
- waltersport.com
news.modernatx.com
fda.gov
gene.com
argenx.com
apnews.com
sec.gov
curevac.com
- etherna.be
ema.europa.eu